Gimeracil/oteracil/tegafur/folinic acid

Drug Profile

Gimeracil/oteracil/tegafur/folinic acid

Alternative Names: Folinic acid/S-1; Gimeracil/oteracil potassium/tegafur/calcium folinate; Gimeracil/oteracil potassium/tegafur/folinic acid; Gimeracil/oteracil/tegafur/calcium folinate; Gimeracil/oteracil/tegafur/leucovorin; S-1/folinic acid; TAS 118

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Taiho Pharmaceutical
  • Class Antineoplastics; Chemoprotectants; Chemosensitisers; Formyltetrahydrofolates; Furans; Pyridines; Pyrimidinones; Small molecules; Triazines; Vitamins
  • Mechanism of Action Antimetabolites; DNA synthesis inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Gastric cancer; Pancreatic cancer
  • Phase I Solid tumours

Most Recent Events

  • 02 Jun 2017 Efficacy and adverse events data from a phase III trial in Pancreatic cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 18 Nov 2016 Clinical trials in Gastric cancer (Adjuvant therapy, Neoadjuvant therapy, Late-stage disease) in Japan (PO) (UMIN000024688)
  • 14 Nov 2016 Taiho pharmaceuticals plans a trial for Gastric cancer (Adjuvant therapy, Neo-adjuvant therapy, Late-stage disease) in Japan (UMIN000024688)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top